GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Voronoi 310210.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

97,500

+2.31%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Voronoi

Its shares trade on KOSDAQ under the ticker 310210.KQ. It has been listed since 24 June 2022. In the fiscal year to 31 December 2025, it reported revenue of ₩7.51bn and a net loss of ₩42.71bn. At that date it held total assets of ₩171.23bn and shareholders' equity of ₩103.80bn.

Voronoi, Inc. engages in the manufacture of novel kinase inhibitors and target protein degrader drugs. The company is headquartered in Incheon, Incheon. The company went IPO on 2022-06-24. The firm is principally engaged in the technology transfer of new drug candidates prior to electroclinical clinical trials. The firm is principally engaged in the research and development of kinase inhibitor as well as others. In addition, the Company is also engaged in the building and supply of new drug development platforms based on artificial intelligence (AI) and research results.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
24 Jun 2022
Website
voronoi.io ↗

Leadership

Pay as last reported

  • Mr. Dae Gwon KimCo-Chief Executive Officer, Director
  • Mr. Hyeon Tae KimCo-Chief Executive Officer, Director
  • Mr. Sang Jin WooChief Financial Officer, Director
  • Mr. Seon Ho KimInternal Auditor
  • Mr. Gwang Bok HuhNon-Executive Independent Director
  • Mr. Sang Wuk LeeNon-Executive Independent Director
  • Mr. Seok Gyun YoonNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Voronoi Inc's AI-driven drug development platforms accelerate novel kinase inhibitor research.
  • Incheon's biotechnology hub supports Voronoi's R&D and manufacturing capabilities.
  • Voronoi's focus on target protein degrader drugs positions it in high-demand therapeutic areas.

Weaknesses

  • Voronoi's reliance on technology transfer before clinical trials may delay market entry.
  • The company's limited product portfolio focuses solely on kinase inhibitors and degraders.
  • Incheon's location may restrict access to global biotech talent and partnerships.

Opportunities

  • Expanding AI applications in drug discovery could enhance Voronoi's R&D efficiency.
  • Growing demand for kinase inhibitors in oncology treatments presents market opportunities.
  • Collaborations with Incheon's biotech cluster could boost Voronoi's innovation pipeline.

Threats

  • Regulatory hurdles in KR could slow Voronoi's clinical trial approvals.
  • Competition from established biotech firms in the Health Care sector remains intense.
  • Economic downturns in KR might reduce funding for biotechnology R&D investments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.